Schonfeld Strategic Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-50,503
| Closed | -$705K | – | 3175 |
|
|
2022
Q3 | $705K | Buy |
+50,503
| New | +$813K | 0.01% | 1510 |
|
|
2022
Q2 | – | Sell |
-22,300
| Closed | -$363K | – | 3176 |
|
|
2022
Q1 | $363K | Sell |
22,300
-71,864
| -76% | -$1.13M | ﹤0.01% | 1558 |
|
|
2021
Q4 | $1.53M | Buy |
94,164
+8,900
| +10% | +$150K | 0.01% | 773 |
|
|
2021
Q3 | $1.27M | Buy |
+85,264
| New | +$1.36M | 0.01% | 871 |
|
|
2020
Q4 | – | Sell |
-5,758
| Closed | -$239K | – | 1955 |
|
|
2020
Q3 | $239K | Sell |
5,758
-10,937
| -66% | -$503K | ﹤0.01% | 1165 |
|
|
2020
Q2 | $800K | Buy |
+16,695
| New | +$1.29M | 0.02% | 673 |
|
|
2020
Q1 | – | Sell |
-5,375
| Closed | -$666K | – | 1620 |
|
|
2019
Q4 | $666K | Sell |
5,375
-26,825
| -83% | -$2.4M | 0.02% | 636 |
|
|
2019
Q3 | $2.14M | Buy |
+32,200
| New | +$2.16M | 0.06% | 303 |
|
|
2017
Q4 | – | Sell |
-10,738
| Closed | -$623K | – | 923 |
|
|
2017
Q3 | $623K | Buy |
+10,738
| New | +$1.16M | 0.06% | 348 |
|
|
2017
Q1 | – | Sell |
-11,134
| Closed | -$1.21M | – | 770 |
|
|
2016
Q4 | $1.21M | Buy |
+11,134
| New | +$1.33M | 0.16% | 199 |
|
Schonfeld Strategic Advisors's ICPT Position: Q4 2022 in Review
Schonfeld Strategic Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 50,503 shares — an estimated $705K sold.
Schonfeld Strategic Advisors first reported a position in ICPT in Q4 2016 and held it in 10 quarters. The position peaked at $2.14M in Q3 2019. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.
- Schonfeld Strategic Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 50,503 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $705K.
- Schonfeld Strategic Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2016 and held it in 10 quarters.
- Schonfeld Strategic Advisors's Intercept Pharmaceuticals, Inc. position peaked at $2.14M in Q3 2019.
- 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.